Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption

Humacyte (NASDAQ:HUMA) is targeting trauma centers and vascular surgery practices for its vascular injury indication. It plans to submit a dialysis access application in November, with a potential FDA decision by May or September 2024. The company reported a Q3 net loss of $15.5M, down from $17.5M a year earlier, and has $64.9M in cash. Humacyte is also beginning a Phase 2a coronary vessel study and focusing on manufacturing and commercial sales.

Humacyte reported Q3 2026 revenue of $1.03M and a net loss of $15.5M. Symvess sales doubled, with 49 hospitals ordering the product. The company plans a BLA filing for ATEV in November 2026. Cash reserves totaled $64.9M. R&D expenses decreased, while G&A expenses increased.

Humacyte's acellular tissue engineered vessel (ATEV), approved for vascular trauma, showed promising results in a phase 3 trial for hemodialysis access. Women with end-stage kidney disease using ATEV had 91 more catheter-free days over 12 months than those with arteriovenous fistulas (AVF). The company plans to seek FDA approval for this new use. Future research will focus on earlier cannulation and cost analysis.

Humacyte (HUMA) reported positive interim Phase 3 trial results for its ATEV in female hemodialysis patients, meeting the primary endpoint. ATEV recipients had more catheter-free days and faster functional access than AV fistula recipients. The company plans to submit a label expansion application to the FDA this quarter. HUMA stock is up 0.31% at $0.41.

Humacyte Inc. (HUMA) reported positive interim results from its V012 Phase 3 trial for a hemodialysis access device, showing superiority over the current standard. The trial was stopped early after meeting its primary endpoint. The company plans to submit an FDA application to expand the device's label. HUMA's stock may be of interest to investors.

Humacyte (HUMA) reported a 44% increase in hospitals ordering its vascular trauma product Symvess, rising to 49 from 34 in Q2 2026. The company expects to exceed its goal of adding 20 new hospitals by year-end. Symvess is FDA-approved for urgent revascularization in adults. Humacyte is also developing other vascular applications.